

## THE ESTIMATION OF LONG-COVID PREVALENCE AND LONG-TERM PERSISTENCE IN ITALIAN CHILDREN AFTER COVID-19 COMPARED TO UN-INFECTED SUBJECTS: AN ANALYSIS USING A PEDIATRIC PRIMARY CARE DATABASE

Costanza Di Chiara 1,2, Elisa Barbieri 1,2, Yu Xi Chen³, Elisa Visonà¹, Sara Cavagnis¹, Giulia Sturniolo¹, Agnese Parca³, Cecilia Liberati¹, Luigi Cantarutti⁴, Angela Lupattelli⁵, Marthe Le Prevost⁶, Giovanni Corrao³, Carlo Giaquinto¹,2,4,

Daniele Donà¹,²\*, Anna Cantarutti³\*

contributed equally as co-last authors

<sup>1</sup>Division of Pediatric Infectious Diseases, Department for Women's and Children's Health, University of Padua, Italy; <sup>2</sup>Penta – Child Health Research, Padua, Italy; <sup>3</sup>Laboratory of Healthcare Research & Pharmacoepidemiology, Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods
University of Milano-Bicocca, Milan, Italy; <sup>4</sup>Società Servizi Telematici-Pedianet, Padova, Italy; <sup>5</sup>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmacoEpidemiology, Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods
University of Milano-Bicocca, Milan, Italy; <sup>4</sup>Società Servizi Telematici-Pedianet, Padova, Italy; <sup>5</sup>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmacoEpidemiology, Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods
University of Milano-Bicocca, Milan, Italy; <sup>4</sup>Società Servizi Telematici-Pedianet, Padova, Italy; <sup>5</sup>PharmacoEpidemiology and Drug Safety Research William (Safety Research Group, Department of PharmacoEpidemiology, Unit of Biostatistics, Epidemiology, Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods
University of Milano-Bicocca, Milan, Italy; <sup>4</sup>Società Servizi Telematici-Pedianet, Padova, Italy; <sup>5</sup>PharmacoEpidemiology and Drug Safety Research Group, Department of PharmacoEpidemiology, Unit of Biostatistics, Epidemiology, Unit of Biostatistics, Ep

Background: Evidence on the incidence of post COVID-19 conditions in the pediatric population is still limited, mainly due to a marked heterogeneity between studies and a lack of works including a comparison group of children unexposed to SARS-CoV-2.

Aim: To evaluate the incidence rate and risk for the onset of new post COVID-19 conditions in a cohort of SARS-CoV-2 exposed and unexposed children and adolescents.

## Methods:


Retrospective nested-cohort study using Pedianet, a comprehensive Italian paediatric primary-care database covering ~12% of the Veneto region pediatric population <15 years of age, linked to the Veneto region COVID-19 swabs and hospitalization registries

Clinical data from previously healthy children diagnosed with COVID-19 (exposed) were compared with 1:1 matched unexposed children from February 1, 2020 to November 30, 2021 (Fig.1)

Incidence rates (IR) of new post COVID-19 conditions were expressed as the number of cases per 100,000 person-months with the appropriate 95% confidence intervals (CI)

Adjusted Hazard ratio (aHR) and 95% CI for the association between exposure to COVID-19 and the onset of new post COVID-19 conditions was estimated using conditional Cox proportional hazard regression.

Fig.1 Time periods, exposure, and matching definitions.



## **Results:**


A total of 3312 paediatrician-, age- and sex-matched previously healthy children (including 1656 exposed [34758 person-months] and 1656 unexposed [34330 person-months]) were studied up to a maximum of 21 months after COVID-19 infection.

Exposed children had a significantly higher IR of at least one new conditions after COVID-19 (IR of 10.6 x 100 person-months [95% CI 9.0-12.3]) compared to unexposed children (IR of 6.5 x 1000 personmonths [95% CI 5.2 - 7.7]) (p< 0.0001).

Overall, **exposed children** had a significantly higher risk of **mental health disorders** (aHR 1.8, 95% CI 1.1 - 3), **neurological disease** (aHR 2.4, 95% CI 1.4 - 4.1), and other conditions, including **skin rashes and smell and taste alterations** (aHR 2, 95%CI 1 - 3.8).

The IR of the onset of new conditions after COVID-19 infection declined over the short, medium, and long term periods in exposed and unexposed children (Fig.2).

Fig.2 IR and 95%CI of selected condition categories in the 3 timepoints post COVID-19.



## **Conclusions:**

Our findings provide evidence of increased IR and risk of the onset of new conditions after COVID-19 infection in children, especially in the short term period.

Further population-based studies are needed to better describe the incidence of new post COVID-19 conditions due to Omicron variant in the pediatric population, as well as the IR of new conditions post other respiratory viral infections.

Funding: This work is partially supported by ORCHESTRA (grant agreement No 101016167)





